Altamira Therapeutics Provides Business Update

Hamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) -- Achieved significant improvement in handling and transport stability of RNA nanoparticles Pursuing partnering opportunities with AM-125 legacy asset in vertigo and / or potential other CNS indications Streamlining corporate structure; switch in financial reporting from Swiss Francs to US Dollars HAMILTON, BERMUDA / May 28, 2024 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing and commercializing RN ...